On the basis of their ability to improve cardiovascular outcomes in high-risk individuals and slow the progression of diabetic kidney disease (DKD), SGLT-2 inhibitors should be considered reasonable second-line treatment options for individuals at risk of cardiovascular events or those with underlying nephropathy. The gene discussed is SLC5A2; the disease is kidney disorder.